The BioLymph study – implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results

References

• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748.
   PubMed Web of Science ®Google Scholar
• Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229–1253.
   PubMed Web of Science ®Google Scholar
• de Leval L, Alizadeh AA, Bergsagel PL, et al. Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022;140(21):2193–2227.
   PubMed Web of Science ®Google Scholar
• Mansouri L, Thorvaldsdottir B, Laidou S, et al. Precision diagnostics in lymphomas – Recent developments and future directions. Semin Cancer Biol. 2022;84:170–183.
   PubMed Web of Science ®Google Scholar
• Harrysson S, Eloranta S, Ekberg S, et al. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021;11(1):9.
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol. 2015;33(23):2516–2522.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood. 2018;131(1):30–38.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Wright GW, Huang DW, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39(12):1643–1653.e3.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–2506.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842–858.
   PubMed Web of Science ®Google Scholar
• Campo E, Cymbalista F, Ghia P, et al. Aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018;103(12):1956–1968.
   PubMed Web of Science ®Google Scholar
• Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European research initiative on CLL. Leukemia. 2022;36(8):1961–1968.
   PubMed Web of Science ®Google Scholar
• Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551–568 e14.
   PubMed Web of Science ®Google Scholar
• Knisbacher BA, Lin Z, Hahn CK, et al. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022;54(11):1664–1674.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.
   PubMed Web of Science ®Google Scholar
• Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood. 2018;131(22):2413–2425.
   PubMed Web of Science ®Google Scholar
• Camus V, Viennot M, Lequesne J, et al. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. Haematologica. 2021;106(1):154–162.
   PubMed Web of Science ®Google Scholar
• Rivas-Delgado A, Nadeu F, Enjuanes A, et al. Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study. Clin Cancer Res. 2021;27(2):513–521.
   PubMed Web of Science ®Google Scholar
• Sprangers MA, Cull A, Bjordal K, et al. The european organization for research and treatment of cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC study group on quality of life. Qual Life Res. 1993;2(4):287–295.
   PubMed Web of Science ®Google Scholar
• Stefansson M, Nygren P. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life. Acta Oncol. 2016;55(9–10):1227–1235.
   PubMed Web of Science ®Google Scholar
• Ekberg S, E Smedby K, Glimelius I, et al. Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century - a Swedish lymphoma register study. Br J Haematol. 2020;189(6):1083–1092.
   PubMed Web of Science ®Google Scholar
• Rosenquist R, Rosenwald A, Du MQ, et al. Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. Haematologica. 2016;101(9):1002–1009.
   PubMed Web of Science ®Google Scholar
• Bonfiglio S, Sutton LA, Ljungström V, et al. BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib. Blood Adv. 2023. DOI:10.1182/bloodadvances.2022008821
   PubMed Web of Science ®Google Scholar
• Horak P, Griffith M, Danos AM, et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of clinical genome resource (ClinGen), cancer genomics consortium (CGC), and variant interpretation for cancer consortium (VICC). Genet Med. 2022;24(9):1991.
   PubMed Web of Science ®Google Scholar
• Ewels PA, Peltzer A, Fillinger S, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38(3):276–278.
   PubMed Web of Science ®Google Scholar
• Foroughi-Asl H, Jeggari, Ashwini, Maqbool, Khurram, Ivanchuk, Vadym, Elhami, Keyvan, Wirta V. BALSAMIC: bioinformatic Analysis pipeLine for SomAtic MutatIons in Cancer (v10.0.3). 2022.
   Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405–424.
   PubMed Web of Science ®Google Scholar
• Wasterlid T, Cavelier L, Haferlach C, et al. Application of precision medicine in clinical routine in haematology-challenges and opportunities. J Intern Med. 2022;292(2):243–261.
   PubMed Web of Science ®Google Scholar
• Haferlach T. Advancing leukemia diagnostics: role of next generation sequencing (NGS) in acute myeloid leukemia. Hematol Rep. 2020;12(Suppl 1):8957.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525–1531.
   PubMed Web of Science ®Google Scholar
• Duncavage EJ, Bagg A, Hasserjian RP, et al. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022;140(21):2228–2247.
   PubMed Web of Science ®Google Scholar
• Tamborero D, Dienstmann R, Rachid MH, et al. Support systems to guide clinical decision-making in precision oncology: the cancer core Europe molecular tumor board portal. Nat Med. 2020;26(7):992–994.
   PubMed Web of Science ®Google Scholar
• Rossi D, Diop F, Spaccarotella E, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017;129(14):1947–1957.
   PubMed Web of Science ®Google Scholar
• Huet S, Salles G. Potential of circulating tumor DNA for the management of patients with lymphoma. J Clin Oncol Oncol Pract. 2020;16(9):561–568.
   PubMedGoogle Scholar
• Sarkozy C, Hung SS, Chavez EA, et al. Mutational landscape of gray zone lymphoma. Blood. 2021;137(13):1765–1776.
   PubMed Web of Science ®Google Scholar